Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT

View Full Paper
Ask AI
Bookmark
Share

Authors

NTNancy TorresSBSushma BharadwajHEHany Elmariah

Discussion

Loading...

Member takes

Overview

Observational analysis shows reduced relapse rates in TP53-mutated AML/MDS patients after hematopoietic cell transplantation, indicating a need for novel strategies in chemo-resistant cases.

Key Points

  • Patients with TP53-mutated AML/MDS demonstrate improved overall survival following hematopoietic cell transplantation.
  • Median overall survival was 25.7 months for TP53-only patients, compared to 10.7 months for CK/MK-only patients.
  • Analysis involved 67 AML/MDS patients treated with hematopoietic cell transplantation and assessed using next-generation sequencing.
  • Findings highlight that chronic graft-versus-host disease may correlate with prolonged overall survival.

Cite This Study

Torres et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d461https://doi.org/10.1182/blood-2025-2525
View Full Paper
Ask AI
Bookmark
Share